NewAmsterdam Pharma Company N.V. (NAMS) has a consensus analyst rating of Buy, based on 10 analysts covering the stock. Of those, 9 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for NAMS is $47.20, representing a +37.0% upside from the current price of $34.44. Price targets range from a low of $37.00 to a high of $55.00.
